argenex SE $ARGX Shares Sold by Artia Global Partners LP

Artia Global Partners LP lessened its holdings in argenex SE (NASDAQ:ARGX) by 17.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 64,699 shares of the company’s stock after selling 13,612 shares during the period. argenex makes up 7.5% of Artia Global Partners LP’s portfolio, making the stock its 2nd biggest position. Artia Global Partners LP’s holdings in argenex were worth $54,409,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. American Century Companies Inc. lifted its position in shares of argenex by 11.6% during the 3rd quarter. American Century Companies Inc. now owns 229,770 shares of the company’s stock worth $169,474,000 after buying an additional 23,864 shares during the period. US Bancorp DE lifted its position in shares of argenex by 37.2% during the 3rd quarter. US Bancorp DE now owns 7,073 shares of the company’s stock worth $5,217,000 after buying an additional 1,919 shares during the period. Sands Capital Management LLC bought a new position in shares of argenex during the 3rd quarter worth approximately $12,262,000. Assenagon Asset Management S.A. acquired a new stake in shares of argenex during the fourth quarter worth approximately $20,475,000. Finally, Fiera Capital Corp increased its holdings in shares of argenex by 12.1% during the third quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock worth $131,030,000 after buying an additional 19,180 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Price Performance

Shares of argenex stock opened at $892.26 on Thursday. The firm has a market cap of $55.49 billion, a P/E ratio of 39.73, a P/E/G ratio of 1.34 and a beta of 0.47. The firm has a 50 day simple moving average of $820.36 and a 200 day simple moving average of $810.81. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. On average, sell-side analysts expect that argenex SE will post 26.19 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ARGX shares. HC Wainwright raised their price objective on shares of argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Guggenheim raised their price objective on shares of argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Citizens Jmp raised their price objective on shares of argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Oppenheimer dropped their price objective on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Finally, Zacks Research raised shares of argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.